Table 1. Impact of adjuvant therapies on 5-year breast cancer mortality.
|
5-year breast cancer mortality
|
|||
|---|---|---|---|
| Without (%) | With (%) | Difference (%) | |
| Radiotherapy | |||
| Breast-conserving surgery (node negative) | 8.9 | 8.0 | 0.9 |
| Breast-conserving surgery (node positive) | 24.3 | 20.9 | 3.4 |
| Mastectomy+axillary clearance (no) | 12.5 | 11.3 | 1.2 |
| Mastectomy+axillary clearance (n+) | 34.0 | 32.1 | 1.9 |
| Chemotherapy | |||
| Polychemotherapy (age <50 years) | 20.4 | 15.7 | 4.7 |
| Polychemotherapy (age 50–69 years) | 21.3 | 18.7 | 1.6 |
| Hormonal therapy | |||
| Tamoxifen (about 5 years) in ER-positive or ER-unknown disease | 11.9 | 8.3 | 3.6 |
| Ovarian ablation or suppression in ER-positive or ER-unknown disease | 18.4 | 16.6 | 1.8 |
Abbreviations: ER=estrogen receptor.
Note: Figures taken from EBCTCG (2005a, 2005b).